文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

代谢功能障碍相关脂肪性肝病患者内脏脂肪代谢评分与全因死亡率的关联：基于美国国家健康与营养检查调查III（1988 - 1994年）的随访研究

Association between metabolic score of visceral fat and all-cause mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a follow-up study based on NHANES III (1988-1994).

作者信息

Huang Guoqing, Zhang Ping-Ping, Wang Tieqiao, Bao Shixue, Mao Yushan

机构信息

Department of Endocrinology, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang Province, China.

Ningbo Center for Healthy Lifestyle Research, Chronic Disease Management Office, The First Affiliated Hospital of Ningbo University, Ningbo, 315000, Zhejiang Province, China.

出版信息

Diabetol Metab Syndr. 2025 Jul 30;17(1):302. doi: 10.1186/s13098-025-01864-9.

DOI:10.1186/s13098-025-01864-9
PMID:40739243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12309096/
Abstract

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, seriously threatening the public health. However, the specific role of metabolic score of visceral fat (METS-VF) as a prognostic marker in the MASLD population remains unclear. In this study, we explored the association and nonlinear relationship between METS-VF and all-cause mortality among MASLD population. METHODS: This study included American adults aged over 20 years with MASLD who participated in the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994) in the United States. Kaplan-Meier curve was used to explore the relationship between different METS-VF levels and all-cause mortality. Multivariable Cox regression analysis was used to explore the independent linear relationship between METS-VF and all-cause mortality. In addition, Cox regression with restricted cubic spline functions and smooth curve fitting were used to evaluate potential nonlinear associations. An inflection point of METS-VF was determined using a two-piece Cox regression model. RESULTS: During an average follow-up period of 23.15 years, there were 1,413 all-cause deaths and the cumulative all-cause mortality proportion was 46.6%. Kaplan-Meier curve revealed that high METS-VF significantly increased the mortality risk in the MASLD population. Multivariate Cox regression analysis revealed that METS-VF was independently associated with all-cause mortality (hazard ratio [HR]: 1.121; 95% confidence interval [CI]: 1.103-1.139; P < 0.001). Cox regression with restricted cubic spline functions and smooth curve fitting showed a J-shaped relationship between METS-VF and all-cause mortality, with an inflection point of 6.394. The HR was 1.068 (95% CI: 1.038-1.099, P < 0.001) before the inflection point and 1.143 (95% CI: 1.122-1.166, P < 0.001) after it. CONCLUSION: This study reveals that higher METS-VF levels are significantly associated with an increased risk of all-cause mortality in individuals with MASLD, characterized by a J-shaped non-linear relationship. This finding provides a new indicator for prognosis assessment in the MASLD population.

摘要

背景：代谢功能障碍相关脂肪性肝病（MASLD）是最常见的慢性肝病，严重威胁公众健康。然而，内脏脂肪代谢评分（METS-VF）作为MASLD人群预后标志物的具体作用仍不明确。在本研究中，我们探讨了METS-VF与MASLD人群全因死亡率之间的关联及非线性关系。 方法：本研究纳入了参与美国第三次全国健康与营养检查调查（NHANES III，1988 - 1994）的20岁以上患有MASLD的美国成年人。采用Kaplan-Meier曲线探讨不同METS-VF水平与全因死亡率之间的关系。多变量Cox回归分析用于探讨METS-VF与全因死亡率之间的独立线性关系。此外，使用带有受限立方样条函数的Cox回归和平滑曲线拟合来评估潜在的非线性关联。使用两段式Cox回归模型确定METS-VF的拐点。 结果：在平均23.15年的随访期内，有1413例全因死亡，累积全因死亡率为46.6%。Kaplan-Meier曲线显示，高METS-VF显著增加了MASLD人群的死亡风险。多变量Cox回归分析显示，METS-VF与全因死亡率独立相关（风险比[HR]：1.121；95%置信区间[CI]：1.103 - 1.139；P < 0.001）。带有受限立方样条函数的Cox回归和平滑曲线拟合显示METS-VF与全因死亡率之间呈J形关系，拐点为6.394。拐点之前HR为1.068（95% CI：1.038 - 1.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/6f0bd1d28e16/13098_2025_1864_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/69cb622c4125/13098_2025_1864_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/d2bd422f8bfb/13098_2025_1864_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/6251a88c3ce2/13098_2025_1864_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/3b2da006a4cd/13098_2025_1864_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/6f0bd1d28e16/13098_2025_1864_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/69cb622c4125/13098_2025_1864_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/d2bd422f8bfb/13098_2025_1864_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/6251a88c3ce2/13098_2025_1864_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/3b2da006a4cd/13098_2025_1864_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7895/12309096/6f0bd1d28e16/13098_2025_1864_Fig5_HTML.jpg

相似文献

[1]
Association between metabolic score of visceral fat and all-cause mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a follow-up study based on NHANES III (1988-1994).

Diabetol Metab Syndr. 2025-7-30

[2]
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999-2018.

Front Nutr. 2025-7-8

[3]
Steatotic Liver Disease as a Risk Enhancer in the Presence of Metabolic Syndrome.

Eur J Prev Cardiol. 2025-6-12

[4]
Dietary inflammatory index and mortality in middle-aged and elderly patients with metabolic syndrome.

Diabetol Metab Syndr. 2025-7-2

[5]
The advanced lung cancer inflammation index has an L-shaped association with prognosis in American adults with metabolic dysfunction-associated fatty liver disease: a cohort study.

Front Nutr. 2025-7-7

[6]
Altered albumin/neutrophil to lymphocyte ratio are associated with all-cause and cardiovascular mortality for advanced cardiovascular-kidney-metabolic syndrome.

Front Nutr. 2025-7-16

[7]
Association between the advanced lung cancer inflammation index and all-cause mortality in the US MASLD/MetALD patient population: a cohort study.

Int J Surg. 2025-4-4

[8]
Elevated pulse wave velocity as a marker of arterial stiffness and its association with mortality in US adults.

Sci Rep. 2025-7-2

[9]
Association between the dietary index for gut microbiota and all-cause/cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease.

Diabetol Metab Syndr. 2025-7-11

[10]
Association between Life's Crucial 9 and metabolic dysfunction-associated steatotic liver disease: the mediating role of neutrophil-percentage-to-albumin ratio.

Front Nutr. 2025-6-6

本文引用的文献

[1]
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus.

Hepatol Commun. 2024-11-1

[2]
Association of metabolic score for visceral fat with all-cause mortality, cardiovascular mortality, and cancer mortality: A prospective cohort study.

Diabetes Obes Metab. 2024-12

[3]
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Obes Facts. 2024

[4]
Surveillance of the liver in type 2 diabetes: important but unfeasible?

Diabetologia. 2024-6

[5]
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.

J Hepatol. 2024-5

[6]
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.

Gut. 2024-3-7

[7]
The newly proposed Metabolic Score for Visceral Fat is a reliable tool for identifying non-alcoholic fatty liver disease, requiring attention to age-specific effects in both sexes.

Front Endocrinol (Lausanne). 2023

[8]
Associations between metabolic score for visceral fat and the risk of cardiovascular disease and all-cause mortality among populations with different glucose tolerance statuses.

Diabetes Res Clin Pract. 2023-9

[9]
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

J Hepatol. 2023-12

[10]
Changing epidemiology, global trends and implications for outcomes of NAFLD.

J Hepatol. 2023-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索